Recursion Pharmaceuticals (RXRX) Goldman Sachs 46th Annual Global Healthcare Conference 2025 summary

Platform validation and technology integration

• AI-driven platform has achieved clinical proof of concept, with predictive models closely matching clinical outcomes, such as the CDK7 molecule's performance in trials.

• Eight compounds have been licensed by partners, and nearly $500 million has been generated from partnership activities, including a $30 million milestone from Roche for a neurology map.

• Integration of biology and chemistry capabilities post-Exscientia merger has enabled seamless technology stack collaboration and accelerated innovation.

• Partnership with MIT on Boltz-2 enabled protein folding and binding affinity modeling 1,000 times faster and 10,000 times cheaper than traditional methods.

• ClinTech business focuses on patient enrichment and clinical trial simulation to drive efficiency and improve trial outcomes.

Pipeline progress and clinical outlook

• Recent FEP data showed unprecedented depth and speed of response, including reversal of dysplasia, with more data expected by year-end.

• CDK7 program is advancing into combination studies, with early monotherapy data showing encouraging efficacy, especially in heavily pretreated patients.

• RBM39 program, derived from phenotypic platform insights, is in clinical trials and aims to validate the approach while targeting oncology indications with biomarker enrichment strategies.

• Portfolio is shifting toward oncology due to clearer regulatory pathways and infrastructure needs, though partnerships continue in I&I and neuroscience.

• PI3K alpha preclinical program demonstrates superior selectivity and aims for a cleaner safety profile compared to competitors.

Business development and financial discipline

• Business development strategy emphasizes creative partnerships over large acquisitions, as seen with the MIT Boltz-2 collaboration.

• Recent strategic and infrastructure changes have reduced annual burn rate by 35%, targeting less than $390 million while maintaining pipeline advancement.

• Internal pipeline prioritization focuses on programs with clear regulatory and commercial paths, balancing risk with partnership-driven revenue.

• Collaborations with NVIDIA and Tempus provide critical technology and data resources, enhancing AI model training and real-world data validation.

• Partnership economics are primarily driven by pharmaceutical partners, with technology collaborations supporting platform scalability.